Acetoacetate Salt.

Medium chain fatty acids bypass carnitine-dependent transport and are oxidised in the liver to acetyl-CoA, which condenses into acetoacetate. One raises the ketone pool from the outside and the other raises it from endogenous production.

Caprylic acid is the medium chain fatty acid most efficiently converted to hepatic ketone bodies, so it raises the same acetoacetate pool the salt supplies directly. The pairing gives an immediate rise plus a slower endogenous one.

Long chain fatty acids need carnitine palmitoyltransferase to enter the mitochondrion before they can be oxidised to acetyl-CoA and then to ketone bodies. Carnitine availability sets the rate of that upstream step feeding the same pathway.

Ketone salts are supplied as sodium, calcium, magnesium or potassium salts, so a meaningful ketone dose carries a meaningful mineral dose with it. Stacking added sodium on top raises total intake more than the label of either product suggests.

The counter-ions in a ketone salt are the same minerals an electrolyte blend supplies, so the two doses add. Formulators count the ketone salt's mineral contribution when setting the electrolyte dose rather than counting it as zero.

Acetoacetate is a weak organic acid and a bolus adds to the circulating acid load, while bicarbonate is the buffer that absorbs it. The two also stack a sizeable sodium dose.

Beta-hydroxybutyrate dehydrogenase interconverts acetoacetate and beta-hydroxybutyrate using NADH, so the ratio between the two ketone bodies tracks mitochondrial redox state. Raising NAD availability shifts where that equilibrium sits.

The interconversion between the two ketone bodies is a nicotinamide-dependent oxidoreduction, so the size of the cellular NAD pool is part of how fast an acetoacetate load is handled. This is cofactor availability for a specific enzyme step, not a claim that adding NAD precursors changes any measured outcome. Blood ketone concentration is a marker of what is circulating, not an outcome in itself.

Leucine is a ketogenic amino acid whose carbon skeleton is broken down through HMG-CoA to acetoacetate and acetyl-CoA. Leucine catabolism and an acetoacetate salt therefore feed the same intermediate from two directions. The overlap is metabolic bookkeeping and does not by itself predict an additive effect on anything a person notices.

Lysine catabolism proceeds through saccharopine and glutaryl-CoA to acetoacetyl-CoA, making lysine one of the ketogenic amino acids. That places it on the same short pathway as an exogenous acetoacetate load. Again this is pathway placement rather than an outcome finding.

Caprylic acid is a medium-chain fatty acid taken up into mitochondria without carnitine and oxidised rapidly to acetyl-CoA, part of which the liver condenses into ketone bodies including acetoacetate. Supplying the salt delivers the end product directly while caprylic acid raises endogenous production. The two raise circulating ketones by different routes, and circulating ketone concentration is a marker.

A calcium acetoacetate salt delivers a fixed amount of calcium with every gram of ketone anion, so the mineral load rises in lockstep with the dose and adds to whatever calcium a person already takes. That mineral, not the ketone, is what limits how much of a calcium-buffered ketone salt can reasonably be used. Anyone already dosing calcium separately should count the salt as a contributor.

Ketone salts are usually blends of mineral counter-ions, and any large anion load taken with sodium and potassium shifts the balance of cations arriving at once. Potassium content is what makes counter-ion choice a matter of total daily intake rather than a free variable. This is a compositional point about the salt, not an interaction between two actives.

Handling an acetoacetate load involves nicotinamide-dependent oxidoreduction, and NMN is a precursor to that cofactor pool. The connection is cofactor supply upstream of the enzyme step. No study has tested the pair, and a shift in a cofactor pool is not an outcome.